Prevalence of liver fibrosis determined by non-invasive methods in patients with metabolic disorders at the Centro Medico Nacional 20 de noviembre

Introduction and Objective

This study aimed to determine the prevalence of liver fibrosis through non-invasive methods in patients with metabolic disorders.

Materials and Methods

Observational, cross-sectional, and retrospective analytical study. Laboratory results and images of patients diagnosed with metabolic alterations in the CMN 20 de Noviembre will be collected.

Results

Among the results obtained, we found that the prevalence of fibrosis was 18.1%, and hepatic steatosis was 59.8%.

Discussion

ALT, C-peptide, and insulin levels were significantly higher in the group with fibrosis. When the variables were dichotomized, an OR of 2.91 (95% CI 1.099 – 7.73) was found for ALT >38.5; Insulin > 17.75, the OR was 3.199 (95% CI 1.20 – 8.5); and for C-peptide > 945 OR 4.049 (95% CI 1.42 – 11.51). The albumin level was significantly lower in this group p = 0.041, with an OR 0.29 (95% CI 0.104 – 0.815), so a value greater than 4.35 represents a protective factor. The NALFD score and FIB4 showed a weak positive correlation with the measurements made with the Fibroscan®.

Conclusions

The determination of liver fibrosis did not correlate through the different non-invasive methods, so it would be best to establish non-invasive liver-specific markers in patients with metabolic disorders and steatohepatitis for the diagnosis of liver fibrosis; since the necessary and accurate diagnostic tools that meet the criteria of efficacy, accuracy, and reliability are not available.

Funding

The resources used in this study were from the hospital without any additional financing

Declaration of interest

The authors declare no potential conflicts of interest.